REMYEL-AI

• Research type

  Research Study

• Full title

  Deep Real-World Data Study in Myelofibrosis Using Artificial Intelligence (REMYEL-AI)

• IRAS ID

  352856

• Contact name

  Tim  D'estrube

• Contact email

  tim.g.d'estrube@gsk.com

• Sponsor organisation

  GSK

• Duration of Study in the UK

  4 years, 5 months, 1 days

• Research summary

  The REMYEL-AI study aims to improve our understanding of myelofibrosis (MF), a rare bone marrow disorder, by using advanced artificial intelligence (AI) techniques to analyse real-world data. This multicenter, retrospective study will review electronic health records (EHRs) of patients with MF across Spain, the UK, Austria, and France, covering the period from July 2015 to December 2027. By employing EHRead®, an innovative system that uses natural language processing (NLP) and machine learning (ML), researchers will extract and analyse data to gain insights into patient characteristics, treatment patterns, and disease progression.

  The study will take place in two phases. Phase 1 involves analysing retrospective data from patients treated between July 2015 and December 2023. Phase 2 will include annual updates of retrospective data from December 2025 to December 2027, allowing for continuous monitoring and analysis of new cases.

  The study focuses on patients newly diagnosed with MF during the recruitment period, including both primary (PMF) and secondary MF (SMF). By leveraging AI and real-world data, this research hopes to provide valuable information to improve care and outcomes for people living with MF.

• REC name

  London - Stanmore Research Ethics Committee

• REC reference

  25/PR/0029

• Date of REC Opinion

  13 Mar 2025

• REC opinion

  Further Information Favourable Opinion